Adaptive Biotech ex-officer plans $6.4M stock sale
Adaptive Biotechnologies Corp (ADPT) received a notice that former officer Harlan Robins intends to sell shares of its common stock under Rule 144.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp (ADPT) received a notice that former officer Harlan Robins intends to sell shares of its common stock under Rule 144. The planned sale covers 261,044 shares, with an indicated aggregate market value of $6,411,240.64. Shares outstanding were listed as 159,595,842 as of 08/18/2026; this is a baseline figure, not the amount being sold.
The shares to be sold were originally acquired on 02/07/2019 as stock option compensation, with the planned transaction described as a cashless exercise / same-day sale through Goldman Sachs & Co. LLC. The notice also lists multiple prior common stock sales by Harlan Robins in the preceding three months, including blocks of 250,000 shares on 07/02/2026 and 207,600 shares plus 284,800 shares on 07/21/2026.
Key Figures
Key Terms
Rule 144 regulatory
cashless exercise financial
same-day sale financial
stock options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing for ADPT disclose about Harlan Robins’ planned sale?
What were the recent ADPT stock sales by Harlan Robins mentioned in the Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.